{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-22-000537","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.297712+00:00","generated_at":"2026-06-22T02:17:51.246811+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KORU Medical Q3 revenue up 28.5% to $7.8M; raises FY2022 guidance to $27.5-28.0M","bullets":["Net sales $7.76M (+28.5% YoY); domestic core +16.2%, international core +46.8%, novel therapies +251.9%.","GAAP net loss $1.2M ($0.03 diluted EPS) vs $1.1M loss ($0.02) in Q3 2021; gross margin 55.7% vs 57.9%.","Full-year 2022 revenue guidance raised to $27.5-28.0M (from $27.0-27.5M); opex guidance lowered to $26.5-27.0M.","Cash $16.4M; management confirms year-end cash minimum of $16.0M.","Novel therapies pipeline: four new Phase II trials, one drug progressed to Phase III."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-22-000537","json":"https://secwatch.observer/filing/0001161697-22-000537.json","markdown":"https://secwatch.observer/filing/0001161697-22-000537.md","text":"https://secwatch.observer/filing/0001161697-22-000537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/0001161697-22-000537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:17:51.246811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46fac46b1b244f01f873495741ba384cf6f09fd7","claim":"KORU Medical Systems, Inc. reported full year 2022 results: revenue $27.5 to $28.0 million. Guidance raised.","evidence_excerpt":"KORU Medical now expects full year 2022 revenue to be in the range of $27.5 to $28.0 million (previously $27.0 to $27.5 million).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/0001161697-22-000537-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$27.5 to $28.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ac935d3907bf6dc039bab3e057cbf2779cf5e820","claim":"KORU Medical Systems, Inc. reported the third quarter ended September 30, 2022 results: revenue $7,760,398, net income $1.2 million, EPS $(0.03) per diluted share.","evidence_excerpt":"$ % Net Sales Domestic Core $ 5,900,042 $ 5,076,294 $ 823,748 $ 16.2% International Core 1,096,746 747,281 349,465 46.8% Novel Therapies 763,610 216,969 546,641 251.9% Total $ 7,760,398 $ 6,040,544 $ 1,719,854 $ 28.5% Total net sales increased $1.7 million, or 28.5%, for the three months ended September 30, 2022, as compared with the same period last year as we","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/0001161697-22-000537-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$7,760,398"},{"label":"Net income","value":"$1.2 million"},{"label":"EPS","value":"$(0.03) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}